Clinical trial · Interventional
Circulating " Cancer Cells / Macrophage " HYbrid Cells in Patients With Sarcoma, Part 2
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating "cancer cell/macrophage" hybrid cells in the peripheral blood and the evolution of this rate over time. The study will be conducted on a population of patients with leiomyosarcoma and treated in the context of routine care. 20 patients will be included: * 10 patients with localized disease. * 10 patients with metastatic disease. For each included patient, blood samples will be collected during baseline visit and up to 24 months after inclusion.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leiomyosarcoma | Leiomyosarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples will be collected at different times. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Patient with leiomyosarcoma
- interventionNames
- Other: Blood samples will be collected at different times.
Primary outcomes (1)
- measure
- The longitudinal evolution of rate of patients with "cancer cell / macrophage" hybrid cells in peripheral blood.
- timeFrame
- 24 months after the end of inclusions.
Secondary outcomes (1)
- measure
- Quantification of circulating hybrid cells in peripheral blood by automatic measurement (Cell Counter Corning) and expressed in number of cells / millilitre of blood.
- timeFrame
- 24 months after the end of inclusions.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient with leiomyosarcoma. 2. Diagnosis of sarcoma histologically confirmed by the RRePS network (Réseau de Référence en Pathologie des Sarcomes et des Viscères) 3. Localized or metastatic disease 4. Newly diagnosed patient who has not yet initiated specific treatment for sarcoma 5. Age ≥ 18 years 6. Patient affiliated to a Social Security system in France. 7. Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedures Exclusion Criteria: 1. Diagnosis of any other histological subtype of soft tissue sarcoma 2. Associated pathology(ies) that may interfere with the study procedure 3. Pregnant or breastfeeding woman 4. Any psychological, family, geographical or sociological condition that does not allow for compliance with the medical follow-up and/or procedures provided for in the study protocol. 5. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
References
Publications (0)
Data not yet available